MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Bromisoval

CAS No. : 496-67-3

MCE 国际站：Bromisoval

产品活性：Bromisoval（BU）具有抗炎作用。

研究领域：Others

作用靶点：Others

In Vitro: Bromisoval (BU) suppresses nitric oxide (NO) releasing and proinflammatory cytokine expression in lipopolysaccharide (LPS)-treat BV2 cells, a murine microglial cell line. Bromisoval suppresses LPS-inducing phosphorylation of signal transducer and activator of transcription 1 (STAT1) and expression of interferon regulatory factor 1 (IRF1). The Janus kinase 1 (JAK1) inhibitor filgotinib suppresses the NO release much more weakly than that of Bromisoval, although filgotinib almost completely prevents LPS-inducing STAT1 phosphorylation. Knockdown of JAK1, STAT1, or IRF1 does not affect the suppressive effects of Bromisoval on LPS-inducing NO. A combination of Bromisoval and filgotinib synergistically suppress the NO releasing. The mitochondrial complex I inhibitor rotenone, which does not prevent STAT1 phosphorylation or IRF1 expression, suppresses proinflammatory mediator expression less significantly than Bromisoval. Bromisoval and rotenone reduce intracellular ATP (iATP) levels to a similar extent. A combination of rotenone and filgotinib suppress NO release in LPS-treated BV2 cells as strongly as Bromisoval.

In Vivo: Bromisoval (Bromvaletone) and carbromal are the most potent central depressants within each series. Depressant activities (ISD₅₀ values) and acute toxicities (LD₅₀ values) in male mice after intraperitoneal injection of Bromisoval are 0.35 (0.30-0.39) and 3.25 (2.89-3.62) mmol/kg, respectively.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  FDA-Approved Drug Library  |  Drug Repurposing Compound Library  |  Anti-COVID-19 Compound Library  |  NMPA-Approved Drug Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Off-patent Drug Library  |  Cysteine Targeted Covalent Library  |  Cysteine Targeted Covalent Fragment Library  |  Antitumor agent-67  |  Catechin 7-O-β-D-glucopyranoside  |  Carbobenzoxyproline  |  ATR-IN-9  |  TBTDC  |  Peucenin 7-O-methyl ether  |  6-Hydroxy-4-methylcoumarin  |  AMT-NHS  |  Nylidrin hydrochloride  |  D-(+)-Fucose  |  OVA Peptide (323-339)  |  Secretin (swine)  |  Bletilloside A  |  Transcriptional Intermediary Factor 2 (TIF2) (740-753)  |  Pep-1 (uncapped)  |  Aspochalasin M  |  Dihydrofuran-3(2H)-one  |  2,6-Difluoropyridine  |  BPK-29 hydrochloride  |  pppApG  |  MEIS-IN-2  |  2′-O-Methyl-8-methyl guanosine  |  Altertoxin I  |  Lithospermoside  |  Acitazanolast  |  FLAG peptide  |  [Des-Tyr1]-Met-Enkephalin  |  α-Carotene  |  myo-Inositol trispyrophosphate hexa-triethylamine  |  Myt1-IN-2

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。